Pathology of Parkinson's Disease

Blue Books of Neurology

Volumn 34, Issue C, 2010, Pages 132-154

  Halliday, Glenda ^a   Murphy, Karen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886045090     PISSN: 1877184X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-1-4160-6641-5.00009-X     Document Type: Chapter

References (165)

1. Polymeropoulos, M.H., Lavedan, C., Leroy, E., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2057.
2. Spillantini, M.G., Schmidt, M.L., Lee, V.M., et al. α-Synuclein in Lewy bodies. Nature 388 (1997), 839–840.
3. Zimprich, A., Biskup, S., Leitner, P., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004), 601–607.
4. Paisan-Ruiz, C., Jain, S., Evans, E.W., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004), 595–600.
5. Kitada, T., Asakawa, S., Hattori, N., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998), 605–608.
6. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004), 1158–1160.
7. Bonifati, V., Rizzu, P., Squitieri, F., et al. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 24 (2003), 159–160.
8. Ramirez, A., Heimbach, A., Grundemann, J., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 (2006), 1184–1191.
9. Klein, C., Lohmann-Hedrich, K., Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol 20 (2007), 453–464.
10. Sharma, M., Mueller, J.C., Zimprich, A., et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. J Med Genet 43 (2006), 557–562.
11. Li, Y.J., Deng, J., Mayhew, G.M., et al. Investigation of the PARK10 gene in Parkinson disease. Ann Hum Genet 71 (2007), 639–647.
12. Snyder, C.H., Adler, C.H., The patient with Parkinson's disease, part I: treating the motor symptoms; part II: treating the nonmotor symptoms. J Am Acad Nurse Pract 19 (2007), 179–197.
13. Ziemssen, T., Reichmann, H., Non-motor dysfunction in Parkinson's disease. Parkinsonism Rel Disord 13 (2007), 323–332.
14. Braak, H., Bohl, J.R., Muller, C.M., et al. Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21 (2006), 2042–2051.
15. de Lau, L.M., Breteler, M.M., Epidemiology of Parkinson's disease. Lancet Neurol 5 (2006), 525–535.
16. Rektor, I., Rektorova, I., Kubova, D., Vascular parkinsonism—an update. J Neurol Sci 248 (2006), 185–191.
17. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983), 979–980.
18. Perl, D.P., Olanow, C.W., The neuropathology of manganese-induced parkinsonism. J Neuropathol Exp Neurol 66 (2007), 675–682.
19. Betarbet, R., Sherer, T.B., MacKenzie, G., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 (2000), 1301–1306.
20. Lai, B.C., Marion, S.A., Teschke, K., Tsui, J.K., Occupational and environmental risk factors for Parkinson's disease. Parkinsonism Rel Disord 8 (2002), 297–309.
21. Clark, L.N., Ross, B.M., Wang, Y., et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69 (2007), 1270–1277.
22. Clark, L.N., Wang, Y., Karlins, E., et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 67 (2006), 1786–1791.
23. Lesage, S., Durr, A., Tazir, M., et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 354 (2006), 422–423.
24. Okubadejo, N.U., An analysis of genetic studies of Parkinson's disease in Africa. Parkinsonism Rel Disord 14 (2008), 177–182.
25. Tan, E.K., Tong, J., Fook-Chong, S., et al. Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 64 (2007), 1056–1058.
26. Ziegler, S.G., Eblan, M.J., Gutti, U., et al. Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91 (2007), 195–200.
27. Biswas, A., Maulik, M., Das, S.K., et al. Parkin polymorphisms: risk for Parkinson's disease in Indian population. Clin Genet 72 (2007), 484–486.
28. Sidransky, E., Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab 83 (2004), 6–15.
29. Braak, H., Del Tredici, K., Rub, U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003), 197–211.
30. Iwai, A., Masliah, E., Yoshimoto, M., et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995), 467–475.
31. Maroteaux, L., Campanelli, J.T., Scheller, R.H., Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8 (1988), 2804–2815.
32. Danzer, K.M., Haasen, D., Karow, A.R., et al. Different species of α-synuclein oligomers induce calcium influx and seeding. J Neurosci 27 (2007), 9220–9232.
33. Fujiwara, H., Hasegawa, M., Dohmae, N., et al. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4 (2002), 160–164.
34. Wakabayashi, K., Hayashi, S., Yoshimoto, M., et al. NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99 (2000), 14–20.
35. Braak, H., Sastre, M., Del Tredici, K., Development of α-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 114 (2007), 231–241.
36. Teismann, P., Schulz, J.B., Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation. Cell Tissue Res 318 (2004), 149–161.
37. Feldmann, A., Illes, Z., Kosztolanyi, P., et al. Morphometric changes of gray matter in Parkinson's disease with depression: a voxel-based morphometry study. Mov Disord 23 (2008), 42–46.
38. Pedersen, K.M., Marner, L., Pakkenberg, H., Pakkenberg, B., No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study. Mov Disord 20 (2005), 164–171.
39. Damier, P., Hirsch, E.C., Agid, Y., Graybiel, A.M., The substantia nigra of the human brain, II: patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (1999), 1437–1448.
40. Fearnley, J.M., Lees, A.J., Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (1991), 2283–2301.
41. Greffard, S., Verny, M., Bonnet, A.M., et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63 (2006), 584–588.
42. McRitchie, D.A., Cartwright, H.R., Halliday, G.M., Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 144 (1997), 202–213.
43. Sanchez-Gonzalez, M.A., Garcia-Cabezas, M.A., Rico, B., Cavada, C., The primate thalamus is a key target for brain dopamine. J Neurosci 25 (2005), 6076–6083.
44. Harding, A.J., Stimson, E., Henderson, J.M., Halliday, G.M., Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125 (2002), 2431–2445.
45. Jellinger, K.A., Cell death mechanisms in Parkinson's disease. J Neural Transm 107 (2000), 1–29.
46. Thannickal, T.C., Lai, Y.Y., Siegel, J.M., Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 (2007), 1586–1595.
47. Hoogendijk, W.J., Pool, C.W., Troost, D., et al. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 118 (1995), 131–143.
48. Halliday, G.M., Li, Y.W., Blumbergs, P.C., et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 27 (1990), 373–385.
49. Halliday, G.M., Macdonald, V., Henderson, J.M., A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 128 (2005), 2272–2280.
50. McGeer, P.L., McGeer, E.G., Glial reactions in Parkinson's disease. Mov Disord 23 (2008), 474–483.
51. Imamura, K., Hishikawa, N., Sawada, M., et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 106 (2003), 518–526.
52. Block, M.L., Hong, J.S., Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 35 (2007), 1127–1132.
53. Zecca, L., Zucca, F.A., Albertini, A., et al. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology 67:Suppl 2 (2006), S8–S11.
54. Beach, T.G., Sue, L.I., Walker, D.G., et al. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol 114 (2007), 419–424.
55. Croisier, E., Moran, L.B., Dexter, D.T., et al. Microglial inflammation in the parkinsonian substantia nigra: relationship to α-synuclein deposition. J Neuroinflamm, 2, 2005, 14.
56. Zhang, W., Qin, L., Wang, T., et al. 3-Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. Faseb J 19 (2005), 395–397.
57. Chen, H., Jacobs, E., Schwarzschild, M.A., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol 58 (2005), 963–967.
58. McGeer, P.L., Schwab, C., Parent, A., Doudet, D., Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol 54 (2003), 599–604.
59. Langston, J.W., Forno, L.S., Tetrud, J., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46 (1999), 598–605.
60. Jellinger, K.A., Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study. J Neural Transm 72 (2007), 91–104.
61. Jellinger, K.A., Prevalence of cerebrovascular lesions in Parkinson's disease: a postmortem study. Acta Neuropathol 105 (2003), 415–419.
62. Mastaglia, F.L., Johnsen, R.D., Kakulas, B.A., Prevalence of stroke in Parkinson's disease: a postmortem study. Mov Disord 17 (2002), 772–774.
63. Jellinger, K.A., Prevalence of Alzheimer lesions in Parkinson's disease. Mov Disord 18 (2003), 1207–1208.
64. Albin, R.L., Young, A.B., Penney, J.B., The functional anatomy of basal ganglia disorders. Trends Neurosci 12 (1989), 366–375.
65. Chaudhuri, K.R., Healy, D.G., Schapira, A.H., Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5 (2006), 235–245.
66. Wolters, E.C., Variability in the clinical expression of Parkinson's disease. J Neurol Sci 266 (2008), 197–203.
67. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., et al. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. J Neurol Sci 20 (1973), 415–455.
68. Otsuka, M., Ichiya, Y., Kuwabara, Y., et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 136 (1996), 169–173.
69. Joel, D., Weiner, I., The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 96 (2000), 451–474.
70. Smith, Y., Kieval, J.Z., Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 23:Suppl (2000), S28–S33.
71. Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., et al. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23:Suppl (2000), S8–S19.
72. Blandini, F., Nappi, G., Tassorelli, C., Martignoni, E., Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62 (2000), 63–88.
73. Orieux, G., Francois, C., Feger, J., et al. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. Neuroscience 97 (2000), 79–88.
74. Rodriguez, M.C., Obeso, J.A., Olanow, C.W., Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 44:Suppl 1 (1998), S175–S188.
75. Smith, I.D., Grace, A.A., Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 12 (1992), 287–303.
76. Brown, P., Williams, D., Basal ganglia local field potential activity: character and functional significance in the human. Clin Neurophysiol 116 (2005), 2510–2519.
77. DeLong, M.R., Wichmann, T., Circuits and circuit disorders of the basal ganglia. Arch Neurol 64 (2007), 20–24.
78. Agid, Y., Ahlskog, E., Albanese, A., et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 14 (1999), 911–913.
79. Benabid, A.L., Pollak, P., Gross, C., et al. Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg 62 (1994), 76–84.
80. Hubble, J.P., Busenbark, K.L., Wilkinson, S., et al. Effects of thalamic deep brain stimulation based on tremor type and diagnosis. Mov Disord 12 (1997), 337–341.
81. Bergman, H., Feingold, A., Nini, A., et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 21 (1998), 32–38.
82. Bergman, H., Deuschl, G., Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord 17:Suppl 3 (2002), S28–S40.
83. Plaha, P., Filipovic, S., Gill, S.S., Induction of parkinsonian resting tremor by stimulation of the caudal zona incerta nucleus: a clinical study. J Neurol Neurosurg Psychiatry 79 (2008), 514–521.
84. Merello, M., Tenca, E., Cerquetti, D., Neuronal activity of the zona incerta in Parkinson's disease patients. Mov Disord 21 (2006), 937–943.
85. Perier, C., Vila, M., Feger, J., et al. Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats. Exp Neurol 162 (2000), 215–224.
86. Pahapill, P.A., Lozano, A.M., The pedunculopontine nucleus and Parkinson's disease. Brain 123 (2000), 1767–1783.
87. Henderson, J.M., Carpenter, K., Cartwright, H., Halliday, G.M., Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 47 (2000), 345–352.
88. Henderson, J.M., Carpenter, K., Cartwright, H., Halliday, G.M., Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123 (2000), 1410–1421.
89. Ozawa, T., Paviour, D., Quinn, N.P., et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127 (2004), 2657–2671.
90. Drake, D.F., Harkins, S., Qutubuddin, A., Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 20 (2005), 335–341.
91. Scherder, E.J., Sergeant, J.A., Swaab, D.F., Pain processing in dementia and its relation to neuropathology. Lancet Neurol 2 (2003), 677–686.
92. Scherder, E., Wolters, E., Polman, C., et al. Pain in Parkinson's disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev 29 (2005), 1047–1056.
93. Sewards, T.V., Sewards, M.A., The medial pain system: neural representations of the motivational aspect of pain. Brain Res Bull 59 (2002), 163–180.
94. Braak, H., Rub, U., Sandmann-Keil, D., et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 99 (2000), 489–495.
95. Rub, U., Del Tredici, K., Schultz, C., et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by α-synuclein immunopositive inclusion body pathology. Neurobiol Aging 23 (2002), 245–254.
96. Djaldetti, R., Shifrin, A., Rogowski, Z., et al. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 62 (2004), 2171–2175.
97. Jellinger, K.A., α-Synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol, 64, 2005, 554.
98. Dubow, J.S., Autonomic dysfunction in Parkinson's disease. Dis Month 53 (2007), 265–274.
99. Wakabayashi, K., Takahashi, H., Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38:Suppl 2 (1997), 2–7.
100. Iwanaga, K., Wakabayashi, K., Yoshimoto, M., et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 52 (1999), 1269–1271.
101. Orimo, S., Amino, T., Itoh, Y., et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109 (2005), 583–588.
102. Orimo, S., Takahashi, A., Uchihara, T., et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17 (2007), 24–30.
103. Takeda, S., Yamazaki, K., Miyakawa, T., Arai, H., Parkinson's disease with involvement of the parasympathetic ganglia. Acta Neuropathol 86 (1993), 397–398.
104. Haehner, A., Hummel, T., Hummel, C., et al. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 22 (2007), 839–842.
105. Ross, G.W., Abbott, R.D., Petrovitch, H., et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21 (2006), 2062–2067.
106. Del Tredici, K., Rub, U., De Vos, R.A., et al. Where does Parkinson disease pathology begin in the brain?. J Neuropathol Exp Neurol 61 (2002), 413–426.
107. Pearce, R.K., Hawkes, C.H., Daniel, S.E., The anterior olfactory nucleus in Parkinson's disease. Mov Disord 10 (1995), 283–287.
108. Bohnen, N.I., Gedela, S., Kuwabara, H., et al. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 254 (2007), 84–90.
109. Doty, R.L., Singh, A., Tetrud, J., Langston, J.W., Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 32 (1992), 97–100.
110. Huisman, E., Uylings, H.B., Hoogland, P.V., A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 19 (2004), 687–692.
111. Swanson, L.W., Petrovich, G.D., What is the amygdala?. Trends Neurosci 21 (1998), 323–331.
112. Lu, J., Sherman, D., Devor, M., Saper, C.B., A putative flip-flop switch for control of REM sleep. Nature 441 (2006), 589–594.
113. Zweig, R.M., Jankel, W.R., Hedreen, J.C., et al. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 26 (1989), 41–46.
114. Boeve, B.F., Silber, M.H., Saper, C.B., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130 (2007), 2770–2788.
115. Hanoglu, L., Ozer, F., Meral, H., Dincer, A., Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior. Clin Neurol Neurosurg 108 (2006), 129–134.
116. Comella, C.L., Sleep disorders in Parkinson's disease: an overview. Mov Disord 22:S17 (2007), S367–S373.
117. Gjerstad, M.D., Alves, G., Wentzel-Larsen, T., et al. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?. Neurology 67 (2006), 853–858.
118. Matsui, H., Nishinaka, K., Oda, M., et al. Excessive daytime sleepiness in Parkinson disease: a SPECT study. Sleep 29 (2006), 917–920.
119. Mercury, M.G., Tschan, W., Kehoe, R., Kuechler, A., The presence of depression and anxiety in Parkinson's disease. Dis Month 53 (2007), 296–301.
120. Zweig, R.M., Cardillo, J.E., Cohen, M., et al. The locus ceruleus and dementia in Parkinson's disease. Neurology 43 (1993), 986–991.
121. Remy, P., Doder, M., Lees, A., et al. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 (2005), 1314–1322.
122. Mayberg, H.S., Solomon, D.H., Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 65 (1995), 49–60.
123. Torack, R.M., Morris, J.C., The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 45 (1988), 497–501.
124. Sakas, D.E., Panourias, I.G., Rostral cingulate gyrus: a putative target for deep brain stimulation in treatment-refractory depression. Med Hypoth 66 (2006), 491–494.
125. Kovari, E., Gold, G., Herrmann, F.R., et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 106 (2003), 83–88.
126. Fregni, F., Ono, C.R., Santos, C.M., et al. Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology 66 (2006), 1629–1637.
127. Diederich, N.J., Goetz, C.G., Stebbins, G.T., Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 20 (2005), 130–140.
128. Onofrj, M., Bonanni, L., Albani, G., et al. Visual hallucinations in Parkinson's disease: clues to separate origins. J Neurol Sci 248 (2006), 143–150.
129. Imamura, K., Wada-Isoe, K., Kitayama, M., Nakashima, K., Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol Scand 117 (2008), 255–259.
130. Williams, D.R., Lees, A.J., Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 4 (2005), 605–610.
131. Harding, A.J., Broe, G.A., Halliday, G.M., Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125 (2002), 391–403.
132. Papapetropoulos, S., McCorquodale, D.S., Gonzalez, J., et al. Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations. Parkinsonism Rel Disord 12 (2006), 253–256.
133. Caballol, N., Marti, M.J., Tolosa, E., Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22:Suppl 17 (2007), S358–S366.
134. Carbon, M., Ma, Y., Barnes, A., et al. Caudate nucleus: influence of dopaminergic input on sequence learning and brain activation in parkinsonism. Neuroimage 21 (2004), 1497–1507.
135. Rinne, J.O., Rummukainen, J., Paljarvi, L., Rinne, U.K., Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26 (1989), 47–50.
136. Lewis, S.J., Dove, A., Robbins, T.W., et al. Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci 19 (2004), 755–760.
137. Owen, A.M., Doyon, J., Dagher, A., et al. Abnormal basal ganglia outflow in Parkinson's disease identified with PET: implications for higher cortical functions. Brain 121 (1998), 949–965.
138. Dubois, B., Pillon, B., Cognitive deficits in Parkinson's disease. J Neurol 244 (1997), 2–8.
139. Pillon, B., Czernecki, V., Dubois, B., Dopamine and cognitive function. Curr Opin Neurol 16:Suppl 2 (2003), S17–S22.
140. Bosboom, J.L., Stoffers, D., Wolters, E., Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm 111 (2004), 1303–1315.
141. Levy, G., Tang, M.X., Cote, L.J., et al. Motor impairment in PD: relationship to incident dementia and age. Neurology 55 (2000), 539–544.
142. Everitt, B.J., Robbins, T.W., Central cholinergic systems and cognition. Annu Rev Psychol 48 (1997), 649–684.
143. Perry, E.K., Curtis, M., Dick, D.J., et al. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48 (1985), 413–421.
144. Dubois, B., Ruberg, M., Javoy-Agid, F., et al. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 288 (1983), 213–218.
145. Rinne, J.O., Myllykyla, T., Lonnberg, P., Marjamaki, P., A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease. Brain Res 547 (1991), 167–170.
146. Haroutunian, V., Serby, M., Purohit, D.P., et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol 57 (2000), 1145–1150.
147. Hurtig, H.I., Trojanowski, J.Q., Galvin, J., et al. α-Synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54 (2000), 1916–1921.
148. Galvin, J.E., Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 20 (2006), 302–310.
149. Whitehouse, P.J., Hedreen, J.C., White, C.L. 3rd, Price, D.L., Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13 (1983), 243–248.
150. Braak, H., Rub, U., Del Tredici, K., Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 248 (2006), 255–258.
151. Harding, A.J., Halliday, G.M., Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 102 (2001), 355–363.
152. Apaydin, H., Ahlskog, J.E., Parisi, J.E., et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59 (2002), 102–112.
153. Mattila, P.M., Roytta, M., Torikka, H., et al. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol 95 (1998), 576–582.
154. Mattila, P.M., Rinne, J.O., Helenius, H., et al. α-Synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 100 (2000), 285–290.
155. Colosimo, C., Hughes, A.J., Kilford, L., Lees, A.J., Lewy body cortical involvement may not always predict dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003), 852–856.
156. de Vos, R.A., Jansen, E.N., Stam, F.C., et al. ‘Lewy body disease’: clinico-pathological correlations in 18 consecutive cases of Parkinson's disease with and without dementia. Clin Neurol Neurosurg 97 (1995), 13–22.
157. McKeith, I.G., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J Alzheimers Dis 9:Suppl (2006), 417–423.
158. Jellinger, K.A., Seppi, K., Wenning, G.K., Poewe, W., Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109 (2002), 329–339.
159. Jendroska, K., The relationship of Alzheimer-type pathology to dementia in Parkinson's disease. J Neural Transm 49 (1997), 23–31.
160. Vermersch, P., Delacourte, A., Javoy-Agid, F., et al. Dementia in Parkinson's disease: biochemical evidence for cortical involvement using the immunodetection of abnormal Tau proteins. Ann Neurol 33 (1993), 445–450.
161. Hughes, A.J., Daniel, S.E., Blankson, S., Lees, A.J., A clinicopathologic study of: 100 cases of Parkinson's disease. Arch Neurol 50 (1993), 140–148.
162. Thomas, B., Beal, M.F., Parkinson's disease. Hum Mol Genet 16:Spec No: 2 (2007), R183–R194.
163. Ischiropoulos, H., Oxidative modifications of α-synuclein. Ann N Y Acad Sci 991 (2003), 93–100.
164. Tansey, M.G., McCoy, M.K., Frank-Cannon, T.C., Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208 (2007), 1–25.
165. Forno, L.S., Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55 (1996), 259–272.